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Abstract (238 words) 
Aims: The hypothesis of “metabolically healthy obesity” implies that, in the absence of 
metabolic dysfunction, individuals with excess adiposity are not at greater cardiovascular risk. 
We tested this hypothesis in a large pan-European prospective study. 
Methods and results: We conducted a case-cohort analysis in the 520,000-person European 
Prospective Investigation into Cancer and Nutrition study (“EPIC-CVD”). During median 
follow-up of 12.2 years, we recorded 7,637 incident coronary heart disease (CHD) cases. Using 
cut-offs recommended by guidelines, we defined obesity and overweight using BMI, and 
metabolic dysfunction (“unhealthy”) as ≥3 of elevated blood pressure, hypertriglyceridemia, low 
HDL-cholesterol, hyperglycemia, elevated waist circumference. We calculated hazard ratios 
(HRs) and 95% confidence intervals (95% CI) within each country using Prentice-weighted Cox 
proportional hazard regressions, accounting for age, sex, centre, education, smoking, diet and 
physical activity. Compared to metabolically healthy normal weight people (reference), HRs 
were 2.15 (95%CI: 1.79; 2.57) for unhealthy normal weight, 2.33 (1.97; 2.76) for unhealthy 
overweight, and 2.54 (2.21; 2.92) for unhealthy obese people. Compared to the reference group, 
HRs were 1.26 (1.14; 1.40) and 1.28 (1.03; 1.58) for metabolically healthy overweight and obese 
people, respectively. These results were robust to various sensitivity analyses. 
Conclusion: Irrespective of BMI, metabolically unhealthy individuals had higher CHD risk than 
their healthy counterparts. Conversely, irrespective of metabolic health, overweight and obese 
people had higher CHD risk than lean people. These findings challenge the concept of 
“metabolically healthy obesity”, encouraging population-wide strategies to tackle obesity. 
 
Keywords: Coronary Heart Disease; Adiposity; Obesity; Metabolic syndrome; Epidemiology
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Introduction 
Overall and abdominal obesity, commonly measured by body mass index (BMI) and waist 
circumference (WC), are important risk factors for coronary heart disease (CHD) (1-3). The 
effects of obesity on CHD are thought to be largely mediated by other cardiometabolic risk 
factors such as insulin resistance, atherogenic dyslipidemia, and type 2 diabetes (4). However, 
many obese people have few or no elevated metabolic risk factors included in the definition of 
the Metabolic Syndrome (MetS) (5), suggesting that there may be a group of obese people – the 
“metabolically healthy obese” – who are not at higher cardiovascular risk (6). There is no 
consensus on the criteria to define this subtype, and an estimated 3 to 57% of obese individuals 
are considered “metabolically healthy obese” depending on the population under study and the 
definition used (7). There has been conflicting evidence on whether metabolically healthy obese 
people are at higher risk of cardiovascular disease (CVD) or type 2 diabetes (8-17), with recent 
meta-analyses challenging the concept of the metabolically healthy obesity by showing higher 
cardiovascular risk among obese individuals with no metabolic syndrome (14, 15, 17, 18). The 
existence of “metabolically healthy obesity” has also been questioned by the latest European 
Society of Cardiology (ESC) guidelines for CVD prevention (19). However, previous studies 
have been limited by incomplete adjustment for potentially important confounders (such as 
physical activity and smoking), short duration of follow-up (and hence small numbers of incident 
CHD events) and use of composite outcomes, such as all-cause mortality. More powerful and 
detailed studies with precisely defined outcomes are therefore needed to clarify the association 
with CHD risk, since heterogeneous effects of obesity according to metabolic health could have 
important implications for risk prevention strategies.  
To address this, we analysed 7,637 incident CHD cases recorded during 12.2 years of follow-up 
from the European Prospective Investigation into Cancer and Nutrition cardiovascular disease 
(EPIC-CVD) case-cohort study. Our primary aim was to examine the separate and combined 
associations of obesity and metabolic health with CHD.  
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Methods 
Study population 
EPIC-CVD is a prospective case-cohort study nested within the European Prospective 
Investigation into Cancer and Nutrition (EPIC) study. Briefly, EPIC includes 366,521 women 
and 153,457 men, mostly aged 35 to 70 years old at baseline, recruited between 1991 and 1999 
at 23 centres across 10 European countries: Denmark, France, Germany, Greece, Italy, the 
Netherlands, Norway, Spain, Sweden, and the United Kingdom. Adults were invited from the 
local general population except in the French centre (women in a national health insurance plan), 
some Italian and Spanish centres (recruited through local blood donor associations), Utrecht (The 
Netherlands) and Florence (Italy) (women invited for population-based breast cancer screening 
programmes) and Oxford (UK) (specifically recruited a substantial proportion of vegetarians). At 
baseline, participants gave a blood sample and completed questionnaires on diet, lifestyle, and 
medical history. Detailed baseline characteristics of the EPIC cohort have been previously 
described (20).  
A case-cohort study nested in a large prospective cohort is similar to a nested case-control study 
with the difference that a random subcohort is selected for use as a reference group, rather than 
matched controls. This design is efficient as it does not require all study participants to have 
exposure measurement and has the advantages of a longitudinal cohort study with prospective 
assessment of key exposures that are not subject to recall bias. Unlike the nested case-control 
design, it allows risk to be measured at any time until the end of follow-up and permits time-to-
event analysis (21). A representative random subcohort of 18,249 participants (62% women), 
stratified by centre, was selected for the EPIC-CVD project, constituting a case-cohort design. 
After exclusion of 609 participants with a prior history of myocardial infarction or stroke at 
baseline, 17,640 subcohort members remained. In total in the EPIC study, 13,964 incident CHD 
cases developed during follow-up, of whom 631 belong to the subcohort. Ethical review boards 
of the International Agency for Research on Cancer and all local institutions where participants 
had been recruited gave approval for the original EPIC study, and all participants gave written 
informed consent.  
Blood pressure measurements were not available for the centres in Norway, Asturias, or Navarra, 
and WC was not recorded in Norway and Umea (22). These centres were excluded from the 
analyses, as well as the French centre due to the limited number of incident CHD events (n=41). 
Further exclusions were performed based on missing exposure and covariate data, described 
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below. All analyses were performed in a sample restricted to participants with no missing data 
(complete-case analysis). Because exclusions due to missing data may result in a selected 
sample, we also used a multiple imputation approach as a sensitivity analysis to compare the 
results with the complete-case approach. A schematic representation of the EPIC-CVD 
case-cohort design and sample selection is given in Supplemental Figure 1. 
Definitions of obesity and metabolic disorders  
Trained health professionals measured blood pressure (BP) (23), weight, height, and waist 
circumference (WC) (24), except in the France and Oxford centres where body size 
measurements were self-reported (25). BMI was calculated as weight (kg) divided by the square 
of height (m
2
). Obesity was defined according to the World Health Organization (26) as 
BMI≥30 kg/m2, overweight as 25≤BMI<30 kg/m2, and normal weight as 18.5≤BMI<25 kg/m2. 
Underweight (BMI<18.5) participants were excluded due to the limited number (n=264, less 
than 1% of the subcohort).  
Total cholesterol, HDL-cholesterol, triglycerides, and glucose were measured in baseline serum 
samples on a Roche auto-analyser (Roche diagnostics, USA) and HbA1c was measured in the 
erythrocyte fraction using the Tosoh-G8 HPLC analyser (Tosoh Bioscience, Japan) at Stichting 
Huisartsen Laboratorium (Etten-Leur, Netherlands). Fasting status was available for 87% of 
participants. Metabolic Syndrome (MetS) was defined according to the 2009 Joint Interim 
Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; 
National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; 
International Atherosclerosis Society; and International Association for the Study of Obesity (5) 
as having three or more of the following metabolic abnormalities: 1) elevated BP, defined as 
systolic BP≥130 and/or diastolic BP≥85 mm Hg and/or use of antihypertensive medication at 
baseline and/or self-reported history of hypertension; 2) hypertriglyceridemia, defined as 
triglycerides≥1.7mmol/L (150mg/dL) or current use of lipid-lowering medication at baseline; 3) 
low HDL-cholesterol, defined as <1.0mmol/L (40mg/dL) for men and <1.3mmol/L (50mg/dL) 
for women; 4) hyperglycemia, defined as fasting blood glucose ≥5.6mmol/L (100mg/dL) or non-
fasting blood glucose≥7.8mmol/L (140mg/dL, with fasting defined as ≥3 hours between last 
meal and blood draw (27)), and/or current use of antidiabetic medication at baseline and/or self-
reported history of diabetes; or 5) elevated waist circumference, defined as WC≥94cm for men 
and WC≥80cm for women. Where information on fasting status was not available (23% of 
participants), the non-fasting cut-off was used for glucose. Diabetes was defined as a self-
reported history and/or HbA1c≥6.5%. 
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Covariate definition 
Validated questionnaires were used to obtain information on education, smoking habits, dietary 
intake (including alcohol intake), and physical activity at study baseline. The Cambridge Index 
of physical activity was derived by combining occupational with recreational activity level to 
produce four groups: active, moderately active, moderately inactive and inactive (28). Usual diet 
over the previous 12 months was assessed using validated country/centre-specific dietary 
questionnaires (24), allowing the calculation of food group, individual energy and nutrient 
intakes (derived from the EPIC nutrient database (29)). To summarize diet quality for adjustment 
purposes, we computed a Mediterranean diet score, ranging from 0-18, with greater scores given 
to higher intakes of fruit, vegetables, legumes, nuts, grains, and fish, lower intakes of red meat 
and dairy, and moderate intake of alcohol (30).  
Outcome ascertainment 
Incident CHD cases were defined as first CHD events, whether non-fatal or fatal, consisting of 
ICD-10 codes I20-I25, which include myocardial infarction, other acute ischemic heart diseases, 
chronic ischemic heart disease and angina pectoris (31). EPIC centres used methods including 
self-report, linkage to primary and secondary care registers, hospital admissions and mortality 
data to ascertain events. Non-fatal CHD events were further validated by additional review of 
individual medical records and/or linkage with registries with validation rates ranging from 82% 
to 100% (32), while fatal CHD events were generally ascertained through mortality registries. 
End of follow-up for CHD events varied between centres and ranged between 2003 and 2010. 
Participants known to have left the country were considered lost to follow-up and censored at 
their date of last follow-up. 
Statistical analyses  
Characteristics of participants in the subcohort were described across body size phenotypes and 
compared using ANCOVA, giving adjusted least square means and percentages (and confidence 
interval) across the six phenotypes. Adjustments were made for centre, sex, age, education, 
smoking status and energy intake (for description of dietary intake only).  
To assess the association of adiposity markers and metabolically-defined body size phenotypes 
with incident CHD, we used Prentice-weighted Cox proportional hazards models with robust 
standard errors to account for the case-cohort design (21). Age was the underlying time scale, 
with entry time defined as the participant’s age at recruitment and exit time as age at first fatal or 
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non-fatal CHD event or censoring (whichever came first). For all analyses, we stratified the 
models by sex and centre. To account for the multi-country design, we followed a 2-stage 
approach where models were fitted separately within country and then country-specific HRs 
were combined using multivariate random-effects meta-analysis (33).   
To assess the shape of associations of BMI and WC with CHD risk, country-specific HRs were 
calculated by comparing quintiles (defined using all participants) of baseline adiposity values 
with the lowest quintile. The pooled hazard ratios were then plotted against mean values of the 
adiposity measure within each quintile, accompanied by a group-specific confidence interval 
derived only from the variance of the log risk in that category (including the reference quintile)  
(34). As associations were approximately log-linear, we calculated HRs associated with 1 
standard deviation (SD) higher baseline value (4.10 kg/m
2
 for BMI, 12.7 cm for WC). 
Heterogeneity between countries was quantified using the I
2
 statistic (35). 
For analyses of adiposity measures, Model 0 was adjusted for baseline age and smoking status 
(never, former, current). Model 1 was further adjusted for highest educational level (no 
schooling/primary, secondary, vocational/university), physical activity, Mediterranean diet score, 
energy and alcohol intake. Model 2 was further adjusted for the different body size markers, i.e. 
WC for BMI and BMI for WC. In Model 3, to explore biological pathways potentially 
underlying the associations, we adjusted for baseline age, smoking status, and intermediate 
cardiovascular risk factors: blood cholesterol (total and HDL), systolic blood pressure and 
diabetes. Interactions on the multiplicative scale between BMI and WC and between BMI and 
MetS were formally tested.  
For analyses of metabolically-defined body size phenotypes, Model A was adjusted for baseline 
age, smoking status (never, former, current) and highest educational level (no schooling/primary, 
secondary, vocational/university). To investigate the potential mediating effect of lifestyle habits 
(36, 37) on the association between metabolically-defined body size phenotypes and CHD risk, 
we compared Model A to Model B, which further included adjustment for physical activity 
(Cambridge index: inactive, moderately inactive, moderately active, active), alcohol 
consumption (g ethanol/day), Mediterranean diet score and energy intake (kcal/day).  
The primary complete-case analyses included only participants with non-missing data on 
anthropometric measurements, blood pressure, blood biomarkers and all covariates, with 
sensitivity analyses that maximised the number of participants by only excluding those with 
missing data on the covariates in each analysis model. Additional sensitivity analyses performed 
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were: 1) excluding the first 2 years of follow-up to minimise the potential for reverse causality; 
2) including only “hard” CHD events, i.e. myocardial infarction and coronary death; 3) including 
only events validated with a high level of certainty; 4) restricting analyses to “never smokers” 
only, to apply more rigid control for smoking; 5) separately for men and women to investigate 
potential differences by sex. For comparability with other studies, we also performed sensitivity 
analyses with different definitions of obesity or metabolic health: 6) excluding the WC criterion 
from the definition of MetS, modifying the definition of metabolically healthy to be <2 
abnormalities (17, 38); 7) defining metabolically healthy participants as having none of four 
possible abnormalities (elevated blood pressure, triglyceridemia, hyperglycemia, low HDL-
cholesterol); 8) using abdominal obesity index defined as WC≥102cm for men and WC≥88cm 
for women. For the latter, a model (Model C) was fitted including BMI as a continuous 
covariate. Finally, 9) we used a multiple imputation approach to impute the missing values for 
the non-systematically missing variables (i.e. after exclusion of the centres with no data on blood 
pressure or waist circumference). Five imputed datasets were generated and estimates were 
combined using Rubin’s rules.   
All analyses were performed with SAS 9.3 (SAS Institute, Cary, NC) and STATA MP 13.1. We 
summarize the key aspects of the modelling strategy in Supplemental Figure 2. 
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Results 
After exclusions, there were 10,474 subcohort participants and 7,637 incident CHD cases (394 of 
whom are also in the subcohort) comprising a total of 17,733 participants who contributed 
117,829 person-years at risk in the complete-case analysis. 63% of subcohort participants were 
female and the mean (SD) age and BMI were 53.6 (9.3) years and 26.1 (4.1) kg/m
2 
respectively 
(Table 1). Median follow-up was 12.2 years (interquartile range: 9.7 – 13.6). 15.8% of subcohort 
participants were obese, 25.6% had MetS, whilst 45.2% of obese participants were 
“metabolically healthy”. Metabolically healthy obese participants were younger and had lower 
BMI than obese participants with MetS (p<0.0001). The metabolically healthy obese had worse 
metabolic parameters (higher lipid levels, blood pressure, HbA1c, C-reactive protein), had higher 
red meat intake, were less likely to be current smokers, more likely to be inactive and less 
educated than metabolically healthy normal weight participants (all p<0.0001, Table 1). The 
proportion of obese participants ranged from 11% in the UK to 30% in Greece and the 
proportion of obese participants who were metabolically healthy ranged from 31.7% in Germany 
to 57.9% in Spain (Supplemental Table 1).  
Associations between body size and CHD 
There was a positive approximately log linear association between BMI and CHD risk (Figure 1 
and Table 2) after adjusting for potential confounders (Model 1): HR per-standard deviation = 
1.25 (95% CI: 1.19, 1.32), p<0.0001. While the association was almost perfectly log-linear from 
quintile 1 to 4, departure from log-linearity was observed at the highest quintile. The risk of 
CHD almost doubled comparing the highest quintile (mean BMI = 32.7 kg/m
2
) to the lowest 
quintile (mean BMI=21.5 kg/m
2
) (HR=1.96 [95% CI 1.66, 2.32], p<0.0001). The association was 
substantially less strong after adjustment for WC (HR =1.06 [95% CI 0.97, 1.15], p=0.20), likely 
reflecting the effect of lean mass and peripheral adipose tissue. The association was also 
substantially attenuated in a model adjusted for intermediate cardiometabolic risk factors (blood 
pressure, total and HDL-cholesterol, diabetes) (HR =1.05 [95% CI 1.01, 1.10], p=0.03, Table 2). 
There was moderate heterogeneity across countries. Results were very similar in sensitivity 
analyses that use all available individuals with complete data for each model in turn 
(Supplemental Table 2). However, results with multiply imputed data showed that, despite 
being strongly attenuated, the HRs remained significant when adjusted for WC or for 
intermediate CVD risk factors (Supplemental Table 3). WC also had positive approximately 
linear associations with CHD (Figure 1, Table 2), which were robust to adjustment for BMI 
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(HR=1.24 [95% CI 1.10, 1.40], p<0.0001). Adjustment for cardiometabolic factors substantially 
attenuated the association (Figure 1, Table 2).  
There was a significant interaction between BMI and WC (p=0.005), with a weaker association 
observed in the upper tertile of each anthropometric factor (Figure 2). For BMI, the HR per-
standard deviation increase was 1.27 (95% CI 1.17, 1.38) in the lowest tertile of WC, whereas it 
was 1.10 (95% CI 1.03, 1.16) in the highest tertile. The association of WC with CHD was 
stronger at every level of BMI than any of the associations of BMI with CHD across the tertiles 
of WC: the HR per-standard deviation increase of WC was 1.65 (95% CI 1.43, 1.89) in the 
lowest tertile of BMI and 1.29 (95% CI 1.21, 1.38) in the highest tertile of BMI. 
Associations between metabolically-defined body size phenotypes and CHD 
Compared to the normal weight participants without MetS (reference group), all other 
metabolically-defined body size phenotypes were at significantly higher risk of CHD (Figure 3) 
in a fully adjusted model (Model B). Metabolically healthy obese individuals were at higher risk 
of CHD (HR=1.28 [95% CI 1.03, 1.58], p=0.02) but this was considerably lower than the risk in 
metabolically unhealthy groups. MetS was strongly positively associated with CHD risk, 
regardless of adiposity, with a HR of 2.15 (95% CI 1.79, 2.57: p<0.0001) for metabolically 
unhealthy normal weight participants with MetS and a HR of 2.54 (95% CI 2.21, 2.92: 
p<0.0001) in their obese counterparts. Results were generally consistent across countries 
(Supplemental Figure 3; Figure 3). Similar results were obtained from models unadjusted for 
physical activity and diet (Model A): the HRs were 1.25 (95% CI 1.14, 1.38) and 1.27 (95% CI 
1.03 – 1.57) in the healthy overweight and obese, and 2.17 (95% CI 1.82, 2.59), 2.35 (95% CI 
2.02, 2.74) and 2.63 (95% CI 2.30, 3.01) in the unhealthy normal weight, overweight and obese, 
respectively. There were no significant interactions between BMI and MetS (p=0.19).  
Sensitivity analyses show similar results after excluding the first 2 years of follow-up 
(Supplemental Table 4), when analyses were restricted to “harder” CHD events only 
(Supplemental Table 5), or when restricting the sample to non-smokers only (Supplemental 
Table 6). Analyses restricted to events only validated to the highest level of certainty were 
qualitatively similar but less precise (Supplemental Table 7). There was no difference between 
men and women (p for interaction=0.63, Supplemental Table 8). Estimates from the multiple 
imputation showed similar trends with the exception of an HR of greater magnitude for the 
metabolically healthy obese (1.67 [95% CI 1.39; 1.99]) (Supplemental Table 3). 
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Sensitivity analyses using a definition of MetS that excludes the WC criterion showed somewhat 
stronger positive associations for all phenotypes (Supplemental Table 9). Results were 
qualitatively similar to the main analysis (but less precise) when a stricter definition of 
metabolically healthy was used (i.e. having none of the MetS abnormalities) (Supplemental 
Table 10). Finally, when obesity was defined by WC (and not by BMI), and MetS did not 
include the WC criteria, HRs were again qualitatively similar to the main analysis although 
somewhat stronger (Supplemental Table 11). When further adjusted for BMI, HRs were 
attenuated. Agreement between the two definitions of metabolically-defined body size 
phenotypes where body size is defined by BMI or by WC was only moderate, with a weighted 
kappa of 0.667 (Supplemental Table 12).  
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Discussion 
In this prospective case-cohort study with 7,637 CHD cases from 8 European countries 
followed-up for a median of 12.2 years, we assessed the separate and combined effects of body 
size and metabolic health on CHD. We observed higher CHD risk for general and central 
adiposity, as defined by BMI and WC, respectively. Whilst the effect of BMI was substantially 
attenuated on adjustment for WC, the effect of WC appeared to be robust to adjustment for BMI. 
Metabolically healthy overweight and obese individuals were at higher risk of CHD compared to 
their normal weight counterparts. However, CHD risk in metabolically unhealthy individuals 
was markedly higher than in their metabolically healthy counterparts across all BMI categories. 
Our study, which is the largest to address this question in terms of the number of incident CHD 
events, suggests that “metabolically healthy” obesity is not a benign condition. This is of 
particular importance as overweight people (BMI ≥25 and <30) with no traditional 
cardiometabolic risk factors are not recommended for weight loss treatment by recent UK or US 
guidelines (39, 40). The risk of CHD in metabolically healthy overweight or obese individuals 
was significantly lower than in the “metabolically unhealthy” groups, suggesting that obese and 
overweight individuals without metabolic abnormalities are at intermediate cardiovascular risk 
between metabolically healthy normal weight individuals and metabolically unhealthy 
individuals. In support of this hypothesis, we showed that only 6% of the obese had strictly no 
cardiometabolic abnormality vs 31% of the normal weight, and that metabolically healthy obese 
individuals have worse cardiometabolic health than their normal weight counterparts, reflected 
by higher blood pressure, HbA1c, pro-atherogenic lipids, and C-reactive protein. These data 
concur with studies that used repeated measurements to evaluate the evolution of metabolically 
healthy obesity over time, showing that metabolically healthy obese people were more likely to 
go on to develop metabolic abnormalities (and become metabolically unhealthy obese) than their 
normal weight counterparts (41-47). Despite being acknowledged as a risk factor for 
cardiovascular disease, excess weight is not included in the prediction model SCORE (48). This 
algorithm estimates the 10 year risk of fatal CVD and its use is recommended by the ESC 
Guidelines for CVD risk assessment of patients to assist health professionals in their prevention 
and treatment strategies (19). Our results suggest that, even in the absence of multiple traditional 
CVD risk factors (smoking, type 2 diabetes, high blood pressure, high blood cholesterol), 
weight-loss strategies through intensive lifestyle advice (diet, exercise and behaviour 
modifications) or medical therapy (orlistat or bariatric surgery) should be recommended for 
obese patients to try to achieve and maintain a healthy body weight to decrease CVD risk. 
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Overall, these results support a population-wide strategy for prevention of obesity and 
overweight regardless of the initial metabolic status of individuals. 
In accordance with previous evidence on CVD, type 2 diabetes, breast and colorectal cancer (14, 
17, 49-51), normal weight individuals with metabolic abnormalities had twice the risk of normal 
weight individuals without metabolic abnormalities. This is consistent with the adverse effects of 
metabolic factors in cardiovascular health, which are independent of obesity and accumulation of 
fat, and could involve inflammation, high blood pressure, lipotoxicity and atherosclerosis (4, 52). 
We also found that a higher WC was associated with higher risk of CHD at all levels of BMI, 
including for those in the normal weight category. This is in line with pooled results from 11 
prospective studies which found a linear positive association between WC and mortality risk at 
all levels of BMI ranging from 20 to 50 kg/m
2 
(53), advocating for the importance of an 
increased waistline at whole spectrum of BMI. Furthermore, a growing body of literature based 
on novel imaging markers has shown heterogeneity in the cardiovascular phenotype of obesity 
depending on location of adipose depots, with increased risk observed with visceral adipose 
tissue compared to subcutaneous fat (54-56). This implies that targeted visceral fat loss, rather 
than overall weight loss, may be a more efficient treatment of obesity to prevent cardiovascular 
events. Medical therapy with orlistat, which leads to greater reduction in visceral adipose tissue 
compared to placebo in clinical trials (57, 58), is a treatment option recommended by the latest 
ESC guidelines (19).     
Positive associations between BMI and WC and CHD are also consistent with previous evidence 
(1-4). Our study confirms both the shape and magnitude of a combined analysis of 39 
prospective studies (5,259 CHD cases) by the Emerging Risk Factors Collaboration (3), which 
found a HR of 1.29 (1.22-1.37) for an increase in BMI of 4.56kg/m
2
 and 1.32 (1.24-1.40) for an 
increase in WC of 12.6cm. Our results also align with those of the recent study by the Global 
BMI Mortality Collaboration, which found a significantly higher risk of CHD death in both the 
overweight and obesity groups compared with the normal weight group in an analysis including 
3,599,426 participants and 54,872 CHD deaths (1). Although substantially attenuated, an 
independent effect of BMI and WC remained after adjustment for major potential mediators 
(SBP, cholesterol, diabetes), indicating that the excess risk for CHD due to high BMI or WC is at 
least partially mediated by other factors. This is consistent with a pooled analysis of 97 
prospective cohort studies from the Prospective Studies Collaboration (57,161 CHD cases), 
which estimated that these three factors collectively explained 46% of the excess risk due to 
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adiposity (4). The association between adiposity and CHD has been suggested to be causal by 
Mendelian randomization studies, which have shown that genetic scores indexing BMI or waist-
to-hip ratio are associated with risk of CHD (59-61). Similar studies have shown causal 
associations of adiposity with cardiovascular risk factors, supporting the hypothesis of mediation 
by blood pressure and cholesterol (62).      
Our study had various strengths, including its prospective design and its large sample size, 
allowing assessment of risk in various subgroups. Anthropometric factors were mostly measured 
by trained health professionals, which should reduce measurement error, and concomitant 
measurement of weight, height and waist circumference allowed direct comparison of BMI and 
WC in the same participants. The biomarkers measured and information on medical history 
permitted exploration of various commonly used definitions of metabolic syndrome, and the 
extensive information on covariates (smoking, physical activity, diet quality, alcohol, education) 
allowed adjustment for a range of potential confounders. However, we cannot rule out the 
possibility of unmeasured confounding. In particular, as behaviors like physical activity and diet 
are self-reported at a single time point and were therefore prone to measurement error (28, 63), it 
is likely that they were not fully captured.  
Study limitations 
A potential limitation when comparing our results with previous studies is the lack of 
consistency in the definition of metabolically healthy obesity (38, 64). Moreover, by definition, 
the MetS gives a simplified picture of diverse and complex phenotypes. To overcome this 
limitation, we chose the most common definition (14, 15, 17) (absence of the MetS (5)), and 
compared several alternative definitions in sensitivity analyses, all of which gave qualitatively 
similar results. The absence of repeated assessment of metabolic health or adiposity during 
follow-up meant we were unable to assess within-person variability in adiposity and shed light 
on the proportion of metabolically healthy obese individuals who became metabolically 
unhealthy, preventing analyses of “stable metabolically healthy obesity” and “transient 
metabolically healthy obesity”. Finally, we acknowledge that some of the centres included in the 
EPIC study are not representative of the general population, potentially limiting the 
generalizability of our findings. For example, the prevalence of metabolically healthy obesity 
within obese participants (45%) in EPIC-CVD is higher than in some other population-based 
studies (64), suggesting that EPIC participants are likely to be healthier than the general 
population. However, even if the participants are different from the general population, as long 
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as there is enough variability in the exposure (here, obesity and metabolic health markers), CHD 
risk estimates and generalizability of the associations are unlikely to be affected.  
Conclusions 
In this large pan-European study, overweight and obesity were associated with higher risk of 
CHD, even in the absence of metabolic syndrome. The presence of metabolic abnormalities was 
associated with a higher risk of CHD at all levels of adiposity, including in normal weight 
individuals. Overweight and obese individuals without metabolic dysfunction were at 
intermediate risk of CHD between healthy normal weight and metabolically unhealthy 
individuals. Our results highlight the importance of both obesity and metabolic health in CHD 
prevention and do not support the concept of “metabolically healthy obesity”. Population-wide 
prevention and treatment of obesity is therefore warranted, regardless of metabolic health.  
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Figure Legends 
 
Figure 1. Multivariate hazard ratios for coronary heart disease across quintiles of BMI (a,b,c) and waist 
circumference (d,e,f) 
 
Country-specific HRs were estimated from Prentice-weighted Cox proportional hazards models, and 95%CI 
estimated with robust variance, to take into account the case-cohort design. HRs were combined by multivariate 
random-effects meta-analysis across 8 countries and accompanied by a group-specific confidence interval 
(allowing a confidence interval to be attributed to the reference category). Age was used as the primary time 
variable, and analyses were stratified by sex and centre.  n=17,733 (7,637 cases) 
Model 1 (a and d). Adjusted for age, smoking, physical activity, Mediterranean diet score, energy and alcohol 
intake, educational level 
Model 2. Model 1 + adjusted for WC (for BMI, b) or BMI (for WC, e) 
Model 3 (c and f). Adjusted for age, smoking status, systolic blood pressure, total cholesterol, HDL cholesterol, 
history of diabetes 
Abbreviations: BMI, body mass index; WC, waist circumference, CHD, coronary heart disease 
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Figure 2. Multivariate hazard ratios (HRs, Model 1
 a
) for CHD associated with quintiles of BMI per sex-
specific tertile of WC (a,b,c) and quintiles of WC per sex-specific tertile of BMI (d,e,f)  
 
 
a
 Country-specific HRs of CHD were estimated from  Prentice-weighted Cox proportional hazards models, and 
95%CI estimated with robust variance, to take into account the case-cohort design. HRs were combined by 
multivariate random-effect meta-analysis across 8 countries and accompanied by a group-specific confidence 
interval (allowing a confidence interval to be attributed to the reference category). Age was used as the primary 
time variable, and analyses were stratified by sex and centre.  n=17,733 (7,637 cases) 
Model 1: Adjusted for age at baseline, smoking, physical activity, educational level, Mediterranean diet score, 
energy and alcohol intake  
HRs for quintiles of BMI, in the first (a), second (b) and third (c) sex-specific tertile of WC 
Boundaries (cm) by tertiles: Tertile 1, 59-91(M), 54-76(F); Tertile 2, 92-99(M),77-86(F); Tertile 3, 100-151(M), 
87-137(F) .  
HRs for quintiles of WC, in the first (d), second (e) and third (f) sex-specific tertile of BMI 
Boundaries (kg/m
2
) by tertiles: Tertile 1, 18.5-25.1(M), 18.5-23.8(F); Tertile 2, 25.1-27.9(M),23.8-27.4; Tertile 
3, 27.9-49.4(M), 27.4-62.5(F).  
P for interaction between BMI and WC = 0.005 
Abbreviations: BMI, body mass index; WC, waist circumference; CHD, coronary heart disease 
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Figure 3. Multivariate hazard ratios of CHD in metabolically-defined body size phenotypes.  
 
a
 Country-specific HRs of CHD were estimated from  Prentice-weighted Cox proportional hazards models, and 
95%CI estimated with robust variance, to take into account the case-cohort design. HRs were combined by 
multivariate random-effects meta-analysis across 8 countries. Age was used as the underlying time scale, 
analyses were stratified by sex and centre, HRs adjusted for age, smoking, educational level, physical activity, 
Mediterranean diet score, energy and alcohol intake (Model B). n=17,733 participants (7,637 CHD cases). P for 
interaction between BMI and MetS = 0.19. 
b 
Heterogeneity across 8 European countries 
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Table 1. Baseline characteristics 
a
 of subcohort participants across metabolically defined body size phenotypes  
 
Normal weight Overweight Obese    
 
Metabolically 
healthy normal 
weight  
Metabolically 
unhealthy normal 
weight 
Metabolically  
healthy overweight 
Metabolically 
unhealthy overweight 
Metabolically  
healthy obese 
Metabolically 
unhealthy obese 
p Healthy 
vs 
unhealthy 
obese 
b
 
p Healthy 
obese vs 
normal 
weight 
b
 
Unadjusted 
mean 
c
 
N 4282 368 2761 1403 751 909 
  
 
Women (%) 69 (67, 71) 69 (64, 73) 55 (53, 57) 51 (48, 53) 64 (61, 67) 59 (56, 62) 0.01 0.01 63 
Age (years) 50.8 (50.6, 51.1) 55.5 (54.7, 56.3) 52.3 (51.9, 52.6) 54.8 (54.4, 55.3) 52.8 (52.2, 53.4) 54.4 (53.9, 54.9) <.0001 <.0001 53.6 (9.3) 
BMI (kg/m2) 22.7 (22.6, 22.7) 23.5 (23.3, 23.7) 26.9 (26.9, 27.0) 27.5 (27.4, 27.6) 32.6 (32.5, 32.8) 33.3 (33.2, 33.5) <.0001 NR 26.1 (4.1) 
WC (cm)
d
 79.9 (79.7, 80.1) 85.5 (84.9, 86.2) 88.9 (88.7, 89.2) 93.1 (92.8, 93.5) 101.2 (100.8, 101.7) 105.2 (104.7, 105.6) NR NR 86.3 (12.6) 
Glucose (mmol/l)
 d,e
 4.78 (4.73, 4.83) 5.39 (5.24, 5.54) 4.80 (4.75, 4.86) 5.39 (5.31, 5.47) 4.83 (4.72, 4.93) 5.84 (5.74, 5.94) NR 0.40 5.04 (1.59) 
HbA1c (%) 5.45 (5.43, 5.47) 5.62 (5.56, 5.68) 5.47 (5.45, 5.50) 5.69 (5.66, 5.72) 5.57 (5.52, 5.61) 5.96 (5.92, 6.00) <.0001 <.0001 5.5 (0.6) 
SBP (mmHg)
 d
 127.7 (127.1, 128.3) 137.6 (135.8, 139.3) 131.5 (130.8, 132.2) 139.0 (138.1, 139.9) 135.5 (134.2, 136.7) 143.2 (142.0, 144.3) NR <.0001 132.9 (19.7) 
DBP (mm Hg)
 d
 78.9 (78.5, 79.2) 84.0 (83.0, 85.0) 81.6 (81.2, 81.9) 85.5 (84.9, 86.0) 84.4 (83.7, 85.1) 87.9 (87.2, 88.6) NR <.0001 82 (10.7) 
HDL, chol (mmol/l)
 d,e
 1.60 (1.58, 1.61) 1.17 (1.13, 1.20) 1.48 (1.47, 1.50) 1.15 (1.13, 1.16) 1.46 (1.43, 1.48) 1.10 (1.08, 1.13) NR <.0001 1.48 (0.42) 
Total chol (mmol/L)
 e
 5.82 (5.78, 5.86) 6.35 (6.24, 6.46) 5.99 (5.95, 6.04) 6.33 (6.27, 6.39) 5.94 (5.87, 6.02) 6.23 (6.15, 6.30) <.0001 0.004 6.01 (1.13) 
Non HDL, chol (mmol/l)
 e
 4.22 (4.18, 4.26) 5.18 (5.07, 5.30) 4.51 (4.47, 4.55) 5.19 (5.13, 5.25) 4.49 (4.41, 4.57) 5.12 (5.05, 5.20) <.0001 <.0001 4.53 (1.18) 
CRP (mg/L) 1.58 (1.43, 1.73) 2.06 (1.63, 2.49) 2.20 (2.03, 2.37) 2.63 (2.40, 2.86) 3.74 (3.44, 4.05) 4.39 (4.11, 4.67) 0.001 <.0001 2.34 (4.23) 
Triglycerides (mmol/l)
 d, e
 1.13 (1.10, 1.15) 2.25 (2.17, 2.33) 1.22 (1.19, 1.25) 2.25 (2.20, 2.29) 1.22 (1.16, 1.27) 2.31 (2.25, 2.36) NR 0.003 1.41 (0.93) 
Vegetables (portions/d) 
f 
2.67 (2.62, 2.71) 2.65 (2.52, 2.78) 2.68 (2.63, 2.73) 2.73 (2.66, 2.80) 2.60 (2.51, 2.70) 2.71 (2.62, 2.80) 0.08 0.19 2.54 (1.81) 
Fruit (portions/d) 
g 
2.92 (2.85, 2.99) 2.94 (2.73, 3.15) 3.09 (3.01, 3.17) 3.07 (2.96, 3.18) 3.03 (2.88, 3.18) 3.16 (3.03, 3.30) 0.17 0.19 3.02 (2.29) 
Red meat (portions/d) 
h 
1.03 (1.01, 1.05) 1.09 (1.03, 1.15) 1.12 (1.10, 1.14) 1.14 (1.11, 1.17) 1.15 (1.11, 1.19) 1.21 (1.17, 1.24) 0.05 <.0001 1.09 (0.74) 
Mediterranean diet score  8.84 (8.77, 8.92) 8.64 (8.42, 8.86) 8.75 (8.66, 8.83) 8.76 (8.65, 8.88) 8.72 (8.57, 8.88) 8.59 (8.45, 8.74) 0.21 0.16 8.55 (3.08) 
Energy intake (kcal/day) 2201 (2181, 2220) 2186 (2128, 2243) 2202 (2180, 2224) 2196 (2165, 2226) 2240 (2199, 2280) 2228 (2191, 2265) 0.67 0.08 2149 (623) 
Alcohol (drinks/d) 
i 
1.85 (1.78, 1.91) 1.82 (1.62, 2.01) 1.84 (1.76, 1.92) 1.82 (1.72, 1.93) 1.78 (1.64, 1.92) 1.72 (1.59, 1.85) 0.56 0.36 1.62 (2.13) 
Physical activity (%) 
        
 
  Inactive 22 (21, 24) 25 (21, 29) 23 (22, 25) 27 (25, 29) 31 (28, 34) 32 (29, 34) 0.71 <.0001 23 
  Moderately inactive 34 (32, 35) 39 (35, 44) 34 (32, 36) 36 (33, 38) 29 (26, 33) 34 (31, 37) 0.04 0.02 33 
  Moderately active 24 (23, 25) 19 (14, 23) 22 (21, 24) 19 (17, 22) 20 (17, 23) 18 (16, 21) 0.37 0.02 22 
  Active 20 (19, 22) 16 (12, 21) 20 (19, 22) 17 (15, 20) 19 (17, 22) 16 (13, 19) 0.07 0.63 21 
Education (%) 
        
 
  No schooling / Primary 35 (33, 36) 43 (39, 48) 43 (41, 44) 46 (44, 48) 52 (49, 55) 51 (48, 54) 0.65 <.0001 38 
  Secondary 15 (14, 16) 12 (09, 16) 14 (12, 15) 11 (09, 13) 11 (08, 13) 10 (07, 12) 0.44 0.002 15 
  Vocational/University 50 (48, 51) 44 (40, 49) 44 (42, 46) 43 (40, 45) 37 (34, 41) 40 (37, 43) 0.31 <.0001 47 
Smoking status (%) 
        
 
  Never 42 (40, 44) 38 (33, 43) 45 (44, 47) 41 (38, 43) 46 (42, 49) 44 (41, 48) 0.54 0.04 45 
  Former 29 (27, 30) 24 (20, 29) 31 (29, 33) 33 (30, 35) 34 (31, 38) 32 (29, 35) 0.36 0.002 29 
  Current 30 (28, 31) 38 (34, 42) 24 (22, 25) 27 (24, 29) 20 (17, 23) 23 (20, 26) 0.10 <.0001 26 
 29 
 
 
 
a
 Values are adjusted means or percentages (and confidence interval) from ANCOVA , adjusted for centre, sex, age, education, and smoking, as well as energy intake for 
dietary variables.  
b
 P-values were calculated using F-test  
c 
Unadjusted means (SD) or percentages overall in the subcohort  (n =10,474)  
d 
Values in bold are components of the metabolic syndrome. The test for difference between metabolically healthy and unhealthy is not presented for these variables as it is 
not relevant (NR).  
e 
Conversion factors from mmol/L to mg/dL: glucose x18.02; cholesterol x38.67; triglycerides x88.57 
f
 1 vegetable portion
 
= 80g 
g 
1 fruit portion
 
= 80g 
h 
1 red meat portion
 
= 110g of unprocessed meat and 50g of processed meat 
i 
1 alcoholic drink corresponds to 10g of ethanol 
Abbreviations: BMI, body mass index; WC, waist circumference; chol, cholesterol; CRP, C-reactive protein; NR, not relevant 
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Table 2. Multivariate hazard ratios for coronary heart disease associated with body mass index and waist 
circumference 
 HR
a
 95% CI p-value I
2 b
 95% CI 
Model 0 
c
      
BMI (kg/m
2
) 1.27 (1.21, 1.33) <.0001 44% (0%, 75%) 
Waist circumference (cm) 1.34 (1.26, 1.42) <.0001 47% (0%, 76%) 
Model 1 
d
      
BMI (kg/m
2
) 1.25 (1.19, 1.32) <.0001 46% (0%, 76%) 
Waist circumference (cm) 1.32 (1.24, 1.41) <.0001 51% (0%, 78%) 
Model 2 
e
      
BMI (kg/m
2
) 1.06 (0.97, 1.15) 0.20 19% (0%, 62%) 
Waist circumference (cm) 1.24 (1.10, 1.40) <.0001 43% (0%, 75%) 
Model 3 
f
      
BMI (kg/m
2
) 1.05 (1.01, 1.10) 0.03 0% (0%, 68%) 
Waist circumference (cm) 1.06 (1.00, 1.13) 0.06 34% (0%, 71%) 
 
 
a
 Country-specific HRs were estimated from Prentice-weighted Cox proportional hazards models, and 95%CI 
estimated with robust variance, to take into account the case-cohort design. HRs were combined by multivariate 
random-effects meta-analysis across 8 countries. HRs are expressed per 1 SD increase of anthropometric marker 
(BMI: 4.10kg/m
2
, WC: 12.7cm), with age as the primary time variable, stratified by sex and centre.  n=17,733 
(7,637 cases) 
b
 Heterogeneity across 8 European countries. 
c
 Model 0. HR adjusted for age and smoking 
d
 Model 1. HR adjusted for age, smoking, physical activity, Mediterranean diet score, energy and alcohol intake, 
educational level 
e
 Model 2. Model 1 + waist circumference (for BMI) or BMI (for waist circumference) 
f
 Model 3. HR adjusted for age, smoking, systolic blood pressure, total cholesterol, HDL cholesterol, history of 
diabetes 
Abbreviations: BMI, body mass index; CHD, coronary heart disease 
